Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by MrMugsyon Jul 18, 2021 11:18am
186 Views
Post# 33566734

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:52 week low

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:52 week low Thanks Bagger!

For the first time in ATE's existance, I think we have everything in place to bring H2S awareness to those who matter most ... potential partners and potential suitors.

I was lucky -  I learned about this company by following Knight's Goodman and his transactions with ATE.  That's when I got in on the cheap.  I did my DD to better understand what happened in the past and what the future looks like.

In all honesty, the future is coming together exactly as I had hoped, less the timing, but I've never been involved in a tiny biotech that lacked cash and one the barely survived a Phase 1 meltdown.  I knew it wasn't going to be easy. 

I also didn't expect COVID to be a future factor.  Oh well ... survivors potentially become leaders if you can get through something like that (personal opinion).

Now we have the cash (more on the way) to stand firm during negotiations.  We have a development plan (help from academia and Dalriada who represent the horses we need to move the plan forward).  Finally, we can now move the family of drugs forward (352, 340+, Mesalamine+H2S).  I see new molecules and IP extensions as critical but only possible when we fell into cash.  So - should we have gone to market for cash at 40 cents ($4) and at 60 cents ($6)?  You bet your right testical we should have.

Also, I rely on the 2014 Mesalamine+H2S study as a foreshadowing of what H2S can do for ulcer repair.  I personally would be shocked if we don't see that characteristic of H2S come through during the P3 study ... but that's my own personal belief.

So I don't have the share price to sit still right now and the difference between share price and value is huge (in my opinion).  That's why I started buying again below $4.

Just the way I see it.  
<< Previous
Bullboard Posts
Next >>